Duncker Streett & Co’s Anavex Life Sciences AVXL Stock Holding History

Duncker Streett & Co’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-50	Closed	-$1K	–	486
2021 Q4	$1K	Hold	50	–	–	﹤0.01%	491
2021 Q3	$1K	Hold	50	–	–	﹤0.01%	491
2021 Q2	$1K	Hold	50	–	–	﹤0.01%	483
2021 Q1	$1K	Hold	50	–	–	﹤0.01%	481
2020 Q4	$0	Hold	50	–	–	﹤0.01%	526
2020 Q3	$0	Hold	50	–	–	﹤0.01%	504
2020 Q2	$0	Hold	50	–	–	﹤0.01%	516
2020 Q1	$0	Hold	50	–	–	﹤0.01%	527
2019 Q4	$0	Buy	+50	New	+$131	﹤0.01%	545
2019 Q3	–	Sell	-50	Closed	–	–	276
2019 Q2	$0	Hold	50	–	–	﹤0.01%	553
2019 Q1	$0	Hold	50	–	–	﹤0.01%	563
2018 Q4	$0	Hold	50	–	–	﹤0.01%	566
2018 Q3	$0	Hold	50	–	–	﹤0.01%	588
2018 Q2	$0	Hold	50	–	–	﹤0.01%	594
2018 Q1	$0	Hold	50	–	–	﹤0.01%	596
2017 Q4	$0	Hold	50	–	–	﹤0.01%	591
2017 Q3	$0	Hold	50	–	–	﹤0.01%	599
2017 Q2	$0	Hold	50	–	–	﹤0.01%	611
2017 Q1	$0	Hold	50	–	–	﹤0.01%	628
2016 Q4	$0	Hold	50	–	–	﹤0.01%	619
2016 Q3	$0	Buy	+50	New	+$211	﹤0.01%	612

Other funds holding AVXL

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Duncker Streett & Co's AVXL Position: Q1 2022 in Review

Duncker Streett & Co sold out of Anavex Life Sciences (AVXL) in Q1 2022, closing a stake of 50 shares — an estimated $1K sold.

Duncker Streett & Co first reported a position in AVXL in Q3 2016 and held it in 21 quarters. The position peaked at $1K in Q4 2021. 139 funds tracked by Wall St. Rank hold AVXL as of Q1 2022.

Duncker Streett & Co reported no remaining Anavex Life Sciences position as of Q1 2022 after selling out during the quarter.
Duncker Streett & Co sold 50 Anavex Life Sciences shares in Q1 2022, an estimated $1K.
Duncker Streett & Co first reported a position in Anavex Life Sciences in Q3 2016 and held it in 21 quarters.
Duncker Streett & Co's Anavex Life Sciences position peaked at $1K in Q4 2021.
139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2022.

Based on Duncker Streett & Co's 13F filing for Q1 2022, filed 9 May 2022.